Delgocitinib cream formulation demonstrates a dose-dependent response in adults with mild to severe atopic dermatitis: results from an 8-week randomised Phase IIb trial. - Silverberg JI; Beck LA; Gooderham M; Murrell DF; Wiseman MC; Sørensen L; Jönsson PG; Stein-Gold L (The British journal of dermatology, 2026)